Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 2/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10692169 | 0.83 | CYP2A6 (0.36) | CYP2A6ALDH1A1MAPTSMN1; SMN2CA1 | |
| SCHEMBL10693094 | 0.81 | IFNAR1 (0.44) | CYP2A6ALDH1A1MAPTSMN1; SMN2LOXL2 | |
| SCHEMBL12322015 | 0.75 | CYP2A6 (0.44) | CYP2A6ALDH1A1PNMTLOXL2 | |
| SCHEMBL27002564 | 0.74 | DYRK1A (0.46) | CYP2A6ALDH1A1MAPTCA1CA2 | |
| SCHEMBL10693338 | 0.74 | TSHR (0.45) | CYP2A6ALDH1A1MAPTCA1CA2 | |
| SCHEMBL30350331 | 0.74 | CYP2A6 (0.39) | CYP2A6ALDH1A1MAPTCA1CA2 | |
| SCHEMBL29915143 | 0.74 | DYRK1A (0.46) | CYP2A6ALDH1A1MAPTCA1CA2 | |
| SCHEMBL29153598 | 0.74 | CYP2A6 (0.39) | CYP2A6ALDH1A1MAPTCA1CA2 | |
| SCHEMBL3883853 | 0.73 | ALDH1A1 (0.40) | ALDH1A1MAPTSMN1; SMN2PNMTLOXL2 | |
| SCHEMBL2348991 | 0.70 | KMT2A (0.34) | ALDH1A1MAPTMAPK9MAPK1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| WO-2010058846-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | JAK3, JAK2, JAK1 | CYP2A6 2014/4885ALDH1A1 1378/4885MAPT 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.